Recently, Chongqing Lemei Longyu Pharmaceutical Co., Ltd. ("Lemei Longyu"), a holding grandchild company of Guangxi Wuzhou Zhongheng Group Co., Ltd. (hereinafter referred to as the "Company" or "Zhongheng Group"), has received the Approval Notice for the Marketing Application of Chemical Active Pharmaceutical Ingredient for Nicorandil (Specification: 4.00kg/bag, 1 bag/bottle), which was approved and issued by the National Medical Products Administration (NMPA). Matters concerned are hereby announced as follows:
I. Basic Information of Nicorandil Active Pharmaceutical Ingredient
| Name of Chemical Active Pharmaceutical Ingredient |
Generic Name: Nicorandil English/Latin Name: Nicorandil |
| Packaging Specifications | 4.00kg/bag, 1 bag/bottle |
| Notice No. |
2024YS00170 |
| Registration Standard No. of Chemical Active Pharmaceutical Ingredient |
YBY61952024 |
| Application Item | Marketing Application for Domestic-produced Chemical Active Pharmaceutical Ingredient |
| Validity Period | 24 months |
| Manufacturer |
Name: Chongqing Lemei Longyu Pharmaceutical Co., Ltd. Address: No. 2, Huanan 4th Branch Road, Economic and Technological Development Zone, Changshou District, Chongqing |
|
Approval Conclusion |
In accordance with the Drug Administration Law of the People's Republic of China and relevant provisions, after review, this product meets the relevant requirements for drug registration, and its registration application is approved. The production process, quality standards, and packaging labels shall be implemented in accordance with the attached documents. |
| Validity Period of the Notice | Valid until February 27, 2029 |
II. Other Relevant Information on Nicorandil Active Pharmaceutical Ingredient
Nicorandil for injection is mainly indicated for unstable angina pectoris and acute heart failure. It improves coronary microcirculation, effectively reduces cardiovascular events, and significantly lowers the risk of acute coronary syndrome, bringing substantial clinical benefits to patients.
Nicorandil was originally developed by Chugai Pharmaceutical Co., Ltd. Its tablet and injection formulations were approved for marketing by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan in 1983 and 1993, respectively. The original research drug of nicorandil tablets was approved for marketing in China in 2005. When Lemei Longyu filed the application for nicorandil API this time, Chongqing Lummy Pharmaceutical Co., Ltd., a holding subsidiary of the Group, also submitted a marketing application for the relevant preparations of this product to the National Medical Products Administration (NMPA).












